Risk factor
Low price volatility
Profitability factor
Weak growth
About
Metall Zug AG, through its subsidiaries, engages in the wire processing, medical devices, infection control, technologycluster and infrastructure, and other businesses in Switzerland, rest of Europe, the Americas, the Asia Pacific, and internationally. The company's Wire Processing business unit develops, produces, and distributes semiautomatic and fully automatic machines for cutting and stripping, crimping, sealing, twisting, tinning, printing, quality control, and process and test automation for various wires and cables. This segment also offers software packages for optimizing machine efficiency and utilization for complex applications and connection of data. Its Medical Devices business unit develops, produces, and distributes diagnosis and microsurgery products primarily in the fields of ophthalmology, as well as covers applications in the fields of pulmonology and measuring instruments. This business unit offers diagnostics products, including slit lamps, biometry, perimetry, tonometer, and practice management software for clinics and opticians, as well as practice equipment; and surgical products, such as microscopes, floor and roof stands, and accessories. The company's Infection Control business unit provides cleaning, disinfection, and sterilization solutions that are used in hospitals. Its Technologycluster & Infrastructure business unit engages in the management and development of real estate. The company's Others business unit offers cleaning, disinfection and sterilization systems and solutions primarily for use in the pharmaceutical industry; and professional appliances and integrated solutions, such as dishwasher and cooking technology, cleaning agents, and care systems for the hotel and catering industry, care homes, and hospitals. Metall Zug AG was founded in 1887 and is headquartered in Zug, Switzerland.
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITD.
Target Price
The average target price of METN.SW is 821 and suggests 11% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendatio
